Details

Učinkovitost izravnalnih ukrepov po Schengenski konvenciji v Republiki Sloveniji : diplomsko delo
ID Merzel, Rok (Author), ID Debelak, Slavko (Mentor) More about this mentor... This link opens in a new window

.pdfPDF - Presentation file, Download (923,22 KB)
MD5: 415B61309F055D2A34D0FA9DD408BF67
PID: 20.500.12556/rul/f9e08f57-a7da-4417-9dee-9a0cf098b6af

Language:Slovenian
Keywords:Evropska unija, Schengenski pravni red, izravnalni ukrepi, Schengenska konvencija, diplomske naloge
Work type:Bachelor thesis/paper
Typology:2.11 - Undergraduate Thesis
Organization:FU - Faculty of Administration
Place of publishing:Ljubljana
Publisher:[R. Merzel]
Year:2011
Number of pages:XI, 50 str.
PID:20.500.12556/RUL-22022 This link opens in a new window
UDC:341.222(043.2)
COBISS.SI-ID:3802286 This link opens in a new window
Publication date in RUL:11.07.2014
Views:2214
Downloads:385
Metadata:XML DC-XML DC-RDF
:
MERZEL, Rok, 2011, Učinkovitost izravnalnih ukrepov po Schengenski konvenciji v Republiki Sloveniji : diplomsko delo [online]. Bachelor’s thesis. Ljubljana : R. Merzel. [Accessed 24 March 2025]. Retrieved from: https://repozitorij.uni-lj.si/IzpisGradiva.php?lang=eng&id=22022
Copy citation
Share:Bookmark and Share

Similar documents

Similar works from RUL:
  1. Pomen tumorskih matičnih celic in epitelno-mezenhimskega prehoda pri napredovanju nedrobnoceličnega raka pljuč
  2. Gene expression levels of the prolyl hydroxylase domain proteins PHD1 and PHD2 but not PHD3 are decreased in primary tumours and correlate with poor prognosis of patients with surgically resected non-small-cell lung cancer
  3. Proučevanje izražanja gena za fosfatidiletanolamin-N-metiltransferazo v nedrobnoceličnem pljučnem rakavem tkivu
  4. Uporabnost imunohistokemičnega določanja mutacij receptorja za epidermalni rastni faktor pri raku pljuč
  5. Sladkorna bolezen in športna vadba
Similar works from other Slovenian collections:
  1. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small cell lung cancer
  2. Outsourcing predictive biomarker testing in non-small cell carcinoma
  3. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  4. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  5. NSCLC molecular testing in Central and Eastern European countries

Back